We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+25.11%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.83B
AUM Growth
+$194M
Cap. Flow
-$79.7M
Cap. Flow %
-4.36%
Top 10 Hldgs %
49.54%
Holding
75
New
12
Increased
19
Reduced
26
Closed
13

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$49.3M
2
AZN icon
AstraZeneca
AZN
+$40.1M
3
AXSM icon
Axsome Therapeutics
AXSM
+$33.8M
4
GKOS icon
Glaukos
GKOS
+$28.7M
5
UTHR icon
United Therapeutics
UTHR
+$24.3M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$75.6M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$31.5M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$29.6M
4
QURE icon
uniQure
QURE
+$25.8M
5
INSM icon
Insmed
INSM
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 89.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$250M 13.65%
1,550,280
– –
GILD icon
2
Gilead Sciences
GILD
$161B
$139M 7.6%
1,252,312
+202,004
+19% +$23M
VERA icon
3
Vera Therapeutics
VERA
$2.54B
$81.2M 4.44%
2,793,987
– –
UTHR icon
4
United Therapeutics
UTHR
$26.3B
$79.9M 4.37%
190,626
+72,113
+61% +$24.3M
JAZZ icon
5
Jazz Pharmaceuticals
JAZZ
$15.9B
$77.6M 4.24%
588,828
-105,268
-15% -$12.6M
AZN icon
6
AstraZeneca
AZN
$263B
$63.2M 3.46%
411,967
+265,136
+181% +$40.1M
RAPP
7
Rapport Therapeutics
RAPP
$1.95B
$57.8M 3.16%
1,947,579
-48,015
-2% -$857K
BSX icon
8
Boston Scientific
BSX
$65.8B
$55.6M 3.04%
569,427
+138,227
+32% +$14.3M
DXCM icon
9
DexCom
DXCM
$27.6B
$52.5M 2.87%
779,616
+255,922
+49% +$20.3M
ISRG icon
10
Intuitive Surgical
ISRG
$121B
$49.6M 2.71%
110,896
+40,254
+57% +$19.3M
AXSM icon
11
Axsome Therapeutics
AXSM
$12.4B
$47.8M 2.61%
393,499
+299,889
+320% +$33.8M
ROIV icon
12
Roivant Sciences
ROIV
$25.2B
$47.6M 2.61%
3,149,270
+60,456
+2% +$748K
IBB icon
13
PUT
iShares Biotechnology ETF
IBB
$9.31B
$46.9M 2.57%
325,000
-50,000
-13% -$6.82M
VRTX icon
14
Vertex Pharmaceuticals
VRTX
$121B
$46.2M 2.52%
+117,875
New +$49.3M
BBIO icon
15
BridgeBio Pharma
BBIO
$16.5B
$43.2M 2.36%
831,847
-161,246
-16% -$7.86M
UTHR icon
16
PUT
United Therapeutics
UTHR
$26.3B
$40.7M 2.23%
+97,100
New +$32.7M
XBI icon
17
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$40.1M 2.19%
+400,000
New +$36M
RNAM
18
DELISTED
Avidity Biosciences
RNAM
$38.2M 2.09%
875,925
+291,124
+50% +$11.8M
ABBV icon
19
AbbVie
ABBV
$458B
$35M 1.91%
150,966
-114,884
-43% -$23.4M
AVBP icon
20
ArriVent BioPharma
AVBP
$1.48B
$31.3M 1.71%
1,696,752
– –
COGT icon
21
Cogent Biosciences
COGT
$6.79B
$30.6M 1.67%
2,127,941
-227,564
-10% -$2.7M
QURE icon
22
PUT
uniQure
QURE
$2.68B
$29.2M 1.6%
+500,000
New +$9.08M
GKOS icon
23
Glaukos
GKOS
$9.02B
$25.5M 1.4%
+312,994
New +$28.7M
IDYA icon
24
IDEAYA Biosciences
IDYA
$3.41B
$25.1M 1.37%
922,695
-1,225,100
-57% -$29.6M
RYTM icon
25
Rhythm Pharmaceuticals
RYTM
$7B
$24.9M 1.36%
246,966
-339,044
-58% -$31.5M
1
2 3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2025 Portfolio in Review

As of Q3 2025, Sofinnova Investments held 75 positions worth $1.83B, up 12% from $1.64B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Sofinnova Investments withdrew a net $79.7M in Q3 2025, closing 13 positions and reducing 26 holdings. Its most notable exit was Eli Lilly, an estimated $75.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Vertex Pharmaceuticals worth $46.2M.

  • Sofinnova Investments's largest Q3 2025 buy was Vertex Pharmaceuticals: 117,875 shares worth $46.2M.
  • Sofinnova Investments added most to AstraZeneca in Q3 2025, an estimated $40.1M increase.
  • Sofinnova Investments's biggest Q3 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $31.5M.
  • Sofinnova Investments fully exited Eli Lilly in Q3 2025, selling an estimated $75.6M.
  • Sofinnova Investments's ten largest holdings make up 50% of its $1.83B portfolio in Q3 2025.
  • Sofinnova Investments opened 12 new positions and closed 13 in Q3 2025.
  • Sofinnova Investments's portfolio value rose 12% quarter-over-quarter to $1.83B.

Based on Sofinnova Investments's 13F filing for Q3 2025, filed 14 Nov 2025.